TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company, has announced the launch of its first mRNA synthesis kit featuring CleanCap® capping technology. To mark the occasion, the company is donating kits to prominent academic laboratories across the United States and Europe, underscoring its commitment to advancing mRNA research and development.

The newly launched in vitro transcription (IVT) kit brings together TriLink’s high-performing components into a single, user-friendly solution, designed to simplify mRNA synthesis while delivering enhanced performance. Each of the seven selected academic institutions will receive ten kits, capable of producing a combined total of up to 250 mg of capped mRNA. This contribution is intended to support further innovation in the rapidly evolving field of mRNA-based therapeutics.

Institutions receiving the kits include:

The Center for RNA Therapeutics at Houston Methodist Research Institute (HMRI)

The Center of RNA Technologies and Therapeutics at UC San Diego

University Medical Center Utrecht

University of Oxford

Yale School of Medicine

The IVT kit includes several of TriLink’s proprietary technologies:

CleanCap® AG (3′ OMe) for efficient co-transcriptional capping

CleanScribe™ RNA Polymerase to reduce double-stranded RNA (dsRNA)

Modified nucleotides, including N1-methylpseudouridine, for optimized mRNA performance

CleanScript® IVT mix, which enhances overall yield

Compared to other commercially available kits, TriLink’s solution offers up to twice the mRNA yield and as much as 85% less dsRNA, providing researchers with high-quality results and improved experimental efficiency.

“This launch integrates a powerful set of novel IVT components that reflect TriLink’s decades of innovation in mRNA synthesis,” said Justin Barbosa, Vice President & General Manager of TriLink Discovery. “By bringing these technologies together in one kit, we’re not only simplifying workflows but also helping researchers produce more high-quality mRNA per reaction.”

The new kit is the only commercially available IVT product that includes CleanCap® AG (3′ OMe) — a modified cap analog offering over 95% capping efficiency and improved protein expression. The co-transcriptional capping process streamlines mRNA manufacturing, reducing steps, hands-on time, and overall complexity compared to traditional ARCA or enzymatic capping methods.

Trey Martin, CEO of Maravai LifeSciences, emphasized the broader significance of the launch: “This product represents a major step forward in IVT technology. More importantly, by donating the first wave of kits to top-tier academic institutions, we are reinforcing our dedication to the future of mRNA science. Supporting cutting-edge research at the academic level is an investment in the therapies of tomorrow.”

TriLink, with over 25 years of expertise in nucleic acid product development, is widely recognized for its contributions to RNA and oligonucleotide-based therapeutics. Its CleanCap® AG (3′ OMe) analog is already utilized in several commercially approved vaccines, with billions of doses administered globally. The company’s reagents and services are available for research use and GMP manufacturing, enabling applications from early-stage discovery to commercial deployment.

source: https://www.trilinkbiotech.com/press-releases/trilink-biotechnologies-debuts-its-first-mrna-synthesis-kit-with-cleancap-capping-technology